FCS: was shown to inhibit platelets aggregation in vitro mediated by collagen and ristocetin, but not ADP, and demonstrated significant anticoagulant activity, which is connected with its ability to enhance inhibition of thrombin and factor Xa by antithrombin III, as well as to influence von Willebrand factor activity.